Literature DB >> 22720214

CD73 promotes tumor growth and metastasis.

Bin Zhang1.   

Abstract

Our recent data and that of others demonstrate that both tumor and host CD73-generated adenosine promote tumor growth and metastasis in a multifactorial manner. Results with small molecule inhibitors or monoclonal antibodies against CD73 in multiple tumor models suggest that CD73 is a previously unappreciated important target for effective cancer therapy.

Entities:  

Year:  2012        PMID： 22720214      PMCID： PMC3376970          DOI： 10.4161/onci.1.1.18068

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  29 in total

1.  Ecto-5'-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells.

Authors:  Li Wang; Xuerui Zhou; Tingting Zhou; Dong Ma; Sifeng Chen; Xiuling Zhi; Lianhua Yin; Zhimin Shao; Zhouluo Ou; Ping Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2007-08-02       Impact factor: 4.553

2.  Tenascin C interacts with ecto-5'-nucleotidase (eN) and regulates adenosine generation in cancer cells.

Authors:  Rafal Sadej; Kunihiro Inai; Zenon Rajfur; Anna Ostapkowicz; Jon Kohler; Andrzej C Skladanowski; Beverly S Mitchell; Jozef Spychala
Journal:  Biochim Biophys Acta       Date:  2007-11-13

3.  Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.

Authors:  Sebastian F M Häusler; Itsaso Montalbán del Barrio; Jenny Strohschein; P Anoop Chandran; Jörg B Engel; Arnd Hönig; Monika Ossadnik; Evi Horn; Birgitt Fischer; Mathias Krockenberger; Stefan Heuer; Ahmed Adel Seida; Markus Junker; Hermann Kneitz; Doris Kloor; Karl-Norbert Klotz; Johannes Dietl; Jörg Wischhusen
Journal:  Cancer Immunol Immunother       Date:  2011-06-03       Impact factor: 6.968

4.  A2A adenosine receptor protects tumors from antitumor T cells.

Authors:  Akio Ohta; Elieser Gorelik; Simon J Prasad; Franca Ronchese; Dmitriy Lukashev; Michael K K Wong; Xiaojun Huang; Sheila Caldwell; Kebin Liu; Patrick Smith; Jiang-Fan Chen; Edwin K Jackson; Sergey Apasov; Scott Abrams; Michail Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-17       Impact factor: 11.205

5.  Different role of CD73 in leukocyte trafficking via blood and lymph vessels.

Authors:  Annika Ålgars; Marika Karikoski; Gennady G Yegutkin; Patrizia Stoitzner; Jussi Niemelä; Marko Salmi; Sirpa Jalkanen
Journal:  Blood       Date:  2011-02-23       Impact factor: 22.113

6.  CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression.

Authors:  Dachuan Jin; Jie Fan; Long Wang; Linda F Thompson; Aijie Liu; Benjamin J Daniel; Tahiro Shin; Tyler J Curiel; Bin Zhang
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

7.  CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice.

Authors:  Long Wang; Jie Fan; Linda F Thompson; Yi Zhang; Tahiro Shin; Tyler J Curiel; Bin Zhang
Journal:  J Clin Invest       Date:  2011-05-02       Impact factor: 14.808

8.  Altered purinergic signaling in CD73-deficient mice inhibits tumor progression.

Authors:  Gennady G Yegutkin; Fumiko Marttila-Ichihara; Marika Karikoski; Jussi Niemelä; Juha P Laurila; Kati Elima; Sirpa Jalkanen; Marko Salmi
Journal:  Eur J Immunol       Date:  2011-05       Impact factor: 5.532

9.  Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation.

Authors:  K Enjyoji; J Sévigny; Y Lin; P S Frenette; P D Christie; J S Esch; M Imai; J M Edelberg; H Rayburn; M Lech; D L Beeler; E Csizmadia; D D Wagner; S C Robson; R D Rosenberg
Journal:  Nat Med       Date:  1999-09       Impact factor: 53.440

10.  Evidence for the involvement of ecto-5'-nucleotidase (CD73) in drug resistance.

Authors:  P Ujházy; E S Berleth; J M Pietkiewicz; H Kitano; J R Skaar; M J Ehrke; E Mihich
Journal:  Int J Cancer       Date:  1996-11-15       Impact factor: 7.396
View more
  35 in total

1.  CD73-generated adenosine is critical for immune regulation during Toxoplasma gondii infection.

Authors:  Deeqa A Mahamed; Leon E Toussaint; Margaret S Bynoe
Journal:  Infect Immun       Date:  2014-12-01       Impact factor: 3.441

2.  CD73 Promotes Glioblastoma Pathogenesis and Enhances Its Chemoresistance via A2B Adenosine Receptor Signaling.

Authors:  Angela Yan; Michelle L Joachims; Linda F Thompson; Andrew D Miller; Peter D Canoll; Margaret S Bynoe
Journal:  J Neurosci       Date:  2019-03-29       Impact factor: 6.167

3.  Anti-CD73 in cancer immunotherapy: awakening new opportunities.

Authors:  Luca Antonioli; Gennady G Yegutkin; Pál Pacher; Corrado Blandizzi; György Haskó
Journal:  Trends Cancer       Date:  2016-02-01

Review 4.  Nanomaterial-Based Modulation of Tumor Microenvironments for Enhancing Chemo/Immunotherapy.

Authors:  Quoc-Viet Le; Juhan Suh; Yu-Kyoung Oh
Journal:  AAPS J       Date:  2019-05-17       Impact factor: 4.009

5.  CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells.

Authors:  Alessia Grozio; Giovanna Sociali; Laura Sturla; Irene Caffa; Debora Soncini; Annalisa Salis; Nadia Raffaelli; Antonio De Flora; Alessio Nencioni; Santina Bruzzone
Journal:  J Biol Chem       Date:  2013-07-23       Impact factor: 5.157

6.  Ecto-5'-nucleotidase expression is associated with the progression of renal cell carcinoma.

Authors:  Y I Yu; Wei Wang; Lei Song; Wentao Hu; Chi Dong; Hailong Pei; Guangming Zhou; Zhongjin Yue
Journal:  Oncol Lett       Date:  2015-04-23       Impact factor: 2.967

7.  CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer.

Authors:  Jieyao Li; Liping Wang; Xinfeng Chen; Lifeng Li; Yu Li; Yu Ping; Lan Huang; Dongli Yue; Zhen Zhang; Fei Wang; Feng Li; Li Yang; Jianmin Huang; Shuangning Yang; Hong Li; Xuan Zhao; Wenjie Dong; Yan Yan; Song Zhao; Bo Huang; Bin Zhang; Yi Zhang
Journal:  Oncoimmunology       Date:  2017-04-21       Impact factor: 8.110

8.  NTPDase3 and ecto-5'-nucleotidase/CD73 are differentially expressed during mouse bladder cancer progression.

Authors:  Liliana Rockenbach; Elizandra Braganhol; Fabrícia Dietrich; Fabrício Figueiró; Manoella Pugliese; Maria Isabel Albano Edelweiss; Fernanda Bueno Morrone; Jean Sévigny; Ana Maria Oliveira Battastini
Journal:  Purinergic Signal       Date:  2014-01-26       Impact factor: 3.765

Review 9.  Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule.

Authors:  Antonella Chillemi; Gianluca Zaccarello; Valeria Quarona; Manuela Ferracin; Chiara Ghimenti; Massimo Massaia; Alberto L Horenstein; Fabio Malavasi
Journal:  Mol Med       Date:  2013-05-20       Impact factor: 6.354

Review 10.  CD39 and CD73 in immunity and inflammation.

Authors:  Luca Antonioli; Pál Pacher; E Sylvester Vizi; György Haskó
Journal:  Trends Mol Med       Date:  2013-04-17       Impact factor: 11.951
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.